Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among patients with recurrent glioblastoma (GBM) in a phase 2, open-label, single-arm trial....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Reardon, David A., Desjardins, Annick, Vredenburgh, James J., Gururangan, Sridharan, Friedman, Allan H., Herndon, James E., Marcello, Jennifer, Norfleet, Julie A., McLendon, Roger E., Sampson, John H., Friedman, Henry S.
Format: Artigo
Jezik:Inglês
Izdano: 2009
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2844073/
https://ncbi.nlm.nih.gov/pubmed/19562254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-009-9950-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items